About Cord Tissue
Mesenchymal stromal stem cells (MSC) from umbilical cord tissue
Omnigen leads the way
Omnigen constantly invests in new technologies, applications and partnerships in order to provide the future parents with the real benefits of stem cells storage and cell therapy. The primary purpose of our company is the implementation of innovative methods and scientific achievements through research so to improve health. Through this research and development in our modern laboratories, we constantly emerge new services.
The result of this investment is that Omnigen has developed the procedures and protocols for the isolation and cryopreservation of mesenchymal stromal stem cells (MSC) from the umbilical cord and other tissues (bone marrow, adipose tissue, etc.).
The scientists in our company are being trained in the most reputable centers of the world in order to acquire experience in the stem cells field. The isolation of mesenchymal stromal stem cells is performed at the tissue of the umbilical cord called Wharton’s jelly. The implementation of these protocols requires very specialized tissue management techniques, cell and tissue culture and proliferation. These techniques are thoroughly developed, tested and perfected in Omnigen’s laboratories.
This service is an example for the development of science through private initiative in Greece. What we can promise to parents who trust us, and the medical community is that we will continue to invest in bioscience, with the sole purpose to lead the developments in stem cells and cell therapy. The driving force of our company is the will to constantly create new horizons for therapeutic applications from stem cells in all aspects of medicine.
Mesenchymal stem cells are multipotent cells with the capacity to self-multiply and differentiate into other cell types such as osteocytes, chondrocytes, adipocytes, tenontokyttara, myocytes and astrocytes. Scientific community has shown strong interest for these cells because of the abundance of their successful applications in pre-clinical and clinical studies. They are the new hope in the field of regenerative medicine and tissue engineering. Clinical studies have shown that these cells have many applications in regenerative medicine, such as:
Treatments with MSC:
- Cardiovascular disease (myocardial infarction)
- Bone, cartilage, and ligaments
- Skin Restoration
- Trachea Restoration
- Repair of peripheral nerves
Possible therapies with MSC:
- Crohn’s Disease
- Multiple sclerosis
- Traumatic Brain Injury
- Damage to the spinal cord
- Muscular Dystrophy
- Liver tissue
The storage of this valuable material concerns all future parents who decide to store stem cells for potential future use by the family. Mesenchymal stem cells have four important characteristics that support the storage:
- An important feature of these cells is the possibility of further culture and proliferation before or after cryopreservation. This allows the use of the sample more than once. Therefore, the valuable material may be used several times, if necessary, without reducing the amount of cells stored.
- Equally important is the immunosuppressive functions of those cells, which gives the unique possibility of transplantation, even if there is no tissue compatibility between donor and recipient of the graft. This allows to use these cells, not only to the child of which they were harvested, but also from other family members. Therefore, if needed, and always with the consent of the parents, they may be donated for use by a fellow human suffering from a serious disease.
- It should be noted that the mesenchymal stem cells do not give rise to hematopoietic cells, therefore it is mandatory to store also hematopoietic stem cells from the umbilical cord blood. The mesenchymal stem cells may however improve hematopoietic stem cells engraftment and hematogenesis in the case of a transplant. That means that these cells have the capacity to support the hematopoietic stem cell transplantation in order to avoid possible rejection of the graft (GVHD).
- The mesenchymal stem cells isolated from Wharton’s jelly of the umbilical cord are already used experimentally as a culture substrate and proliferation of hematopoietic stem cells (stem cells isolated from umbilical cord blood). Thus, in the near future will likely enable proliferation of hematopoietic stem cells already stored from parents (and will be stored in the future) for use mainly in hematological malignancies.
Future parents should, if they so decide, to store hematopoietic stem cells from umbilical cord blood, and mesenchymal stem cells from Wharton’s jelly. The dual storage of hematopoietic and mesenchymal stem cells is important because it allows for the treatment of diseases relating to the hemopoietic and immune system, and pioneering regenerative medicine and organ repair applications.
Until recently, the isolation of mesenchymal stem cells was performed from bone marrow. Because of the risks / difficulties associated with the above procedure, the search for new tissue sources of mesenchymal stromal cells is essential. The literature reported liver, the periodontal ligament, hair follicles, adipose tissue, umbilical cord, amniotic fluid, placenta and lung.
The most suitable tissue for the isolation of mesenchymal stromal stem cells of fetal origin is the mucous connective tissue surrounding / protecting the blood vessels in the umbilical cord called Wharton’s jelly.
The mesenchymal stromal cells isolated from Wharton’s jelly of the umbilical cord, excel adult mesenchymal cells (e.g. bone marrow) as the former have fewer genetic defects and significantly greater regenerative capacity. The mesenchymal cells located in Wharton’s jelly are cells created during embryogenesis.